Business Context and Reporting Period
Aardvark Therapeutics, Inc. (AARD) is a clinical-stage biopharmaceutical company developing small-molecule therapeutics targeting Bitter Taste Receptors (TAS2Rs) for metabolic diseases, specifically hunger-associated conditions. The company's lead candidate, ARD-101, is in Phase 3 development for hyperphagia associated with Prader-Willi Syndrome (PWS). This filing covers the quarterly period ended March 31, 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(21.6) million | $(9.3) million |
| Operating Expenses | $22.5 million | $10.5 million |
| Research & Development | $16.6 million | $7.8 million |
| General & Administrative | $5.9 million | $2.7 million |
| Cash, Cash Equivalents & Short-Term Investments | $91.2 million | $89.5 million |
| Net Cash Used in Operating Activities | $(18.9) million | $(11.4) million |
| Accumulated Deficit | $(137.5) million | $(67.6) million |
Material Changes vs. Prior Period
- Expense Growth: Total operating expenses increased by $12.0 million (115%) year-over-year. R&D expenses rose $8.8 million, driven by a $7.1 million increase in external costs for CMC, clinical, and toxicology studies, and a $1.7 million increase in personnel costs. G&A expenses increased $3.2 million due to higher headcount and public company compliance costs.
- Liquidity Position: While cash and cash equivalents increased from $47.1 million to $62.4 million, short-term investments decreased significantly from $63.0 million to $28.8 million due to maturities and sales to fund operations. Total liquid assets remained relatively stable at $91.2 million.
- Stock-Based Compensation: Stock-based compensation expense increased to $2.0 million in Q1 2026 from $0.2 million in Q1 2025.
Guidance, Outlook, and Risks
- Clinical Trial Pause: On February 27, 2026, the company voluntarily paused enrollment and dosing in its Phase 3 HERO trial (ARD-101 for PWS), the HERO Open Label Extension, and the Phase 2 POWER and STRENGTH trials (ARD-201 for obesity). This decision followed reversible cardiac observations in a healthy volunteer study.
- Regulatory Engagement: The company is reviewing data and collaborating with the FDA to determine next steps. Management expects to provide further guidance in the second quarter of 2026.
- Liquidity Outlook: Management believes current cash and investments ($91.2 million) are sufficient to fund operations into mid-2027, though the clinical pause may alter expenditure timing.
- Capital Resources: The company has an effective shelf registration statement for up to $400.0 million and an At-The-Market (ATM) facility with Piper Sandler for up to $150.0 million. No shares have been sold under the ATM facility as of March 31, 2026.
- Risk Factors: Significant risks include the uncertainty of resuming clinical trials, the potential for trial redesign, the need for additional capital, and the impact of the clinical pause on the company's stock price and operational timeline.
Investor Verification Checklist
- Clinical Safety Data: Verify the specific nature of the "reversible cardiac observations" and the FDA's feedback on the proposed path forward.
- Timeline Impact: Assess the potential delay to the Phase 3 HERO trial topline data, which was previously expected in Q3 2026.
- Cash Burn Rate: Monitor the adjusted cash burn rate given the pause in clinical enrollment and potential reduction in external CRO costs.
- ATM Utilization: Watch for any utilization of the $150 million ATM facility to extend the cash runway beyond mid-2027.
- ARD-201 Program: Confirm the long-term viability of the ARD-201 combination therapy program given its reliance on the ARD-101 component.